- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars
Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.
Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.
Transcript
What are some best strategies for community practices to stay ahead of market trends in biosimilar reimbursement?
I think practices are going to have to decide which manufacturers they want to be able to partner with. This is where I think the larger practices have an advantage, because if the biosimilar manufacturers do what Amgen did and Amgen went to the top 50 oncology groups in the nation, then you’re going to see other smaller practices not have access to the same level of rebates and discounting that the larger ones do. So, it does speak to the consolidation efforts, that if you’re not part of a larger consortium, you’re not going to be able to get the best price on biosimilars.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
